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Abstract: Mucopolysaccharidosis type II (MPS II) is a rare, life-limiting, X-linked recessive disease characterised by
deficiency of the lysosomal enzyme iduronate-2-sulfatase. Consequent accumulation of glycosaminoglycans leads
to pathological changes in multiple body systems. Age at onset, signs and symptoms, and disease progression are
heterogeneous, and patients may present with many different manifestations to a wide range of specialists.
Expertise in diagnosing and managing MPS II varies widely between countries, and substantial delays between
disease onset and diagnosis can occur. In recent years, disease-specific treatments such as enzyme replacement
therapy and stem cell transplantation have helped to address the underlying enzyme deficiency in patients with
MPS II. However, the multisystem nature of this disorder and the irreversibility of some manifestations mean that
most patients require substantial medical support from many different specialists, even if they are receiving
treatment. This article presents an overview of how to recognise, diagnose, and care for patients with MPS II.
Particular focus is given to the multidisciplinary nature of patient management, which requires input from
paediatricians, specialist nurses, otorhinolaryngologists, orthopaedic surgeons, ophthalmologists, cardiologists,
pneumologists, anaesthesiologists, neurologists, physiotherapists, occupational therapists, speech therapists,
psychologists, social workers, homecare companies and patient societies.
Take-home message: Expertise in recognising and treating patients with MPS II varies widely between countries.
This article presents pan-European recommendations for the diagnosis and management of this life-limiting
disease.
Introduction
Mucopolysaccharidosis type II (MPS II, Hunter syn-
drome, Online Mendelian Inheritance in Man number
309900) is an X-linked, recessive disease that is charac-
terised by deficiency in the activity of the lysosomal
enzyme iduronate-2-sulfatase (I2S), owing to a mutation
in the I2S gene (IDS) [1,2]. Like other mucopolysacchar-
idoses, the enzyme deficiency in MPS II results in the
lysosomal accumulation of glycosaminoglycans (GAGs).
The condition is multisystem in nature, with patients
exhibiting coarsening of facial features, bone and joint
abnormalities, short stature, and changes in the heart,
respiratory system, hearing, and vision [2]. Severely
affected patients have profound neurological involve-
ment, with progressive learning difficulties and beha-
vioural abnormalities, as well as disturbed motor
function [3].
MPS II is one of the most common mucopolysacchari-
doses, with an estimated prevalence of 1 in 140 000-156
000 live births in Europe [4-6]. The disease affects males
almost exclusively, although a few symptomatic females
have been identified [7-10]. Age at onset and disease
progression are heterogeneous: patients typically have a
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symptoms emerging between the ages of 18 months and
4 years, depending on disease severity [2,11,12]. Because
the initial signs and symptoms of MPS II can be non-
specific, identification of patients at a young age can be
problematic, resulting in a substantial delay between dis-
ease onset and diagnosis. Life expectancy varies accord-
ing to disease severity; patients with severe phenotypes
are expected to live for less than 2 decades, whereas
individuals with attenuated forms of MPS II may survive
into their 50s or 60s [2,3,13].
Until recently, the management of patients with MPS
II has been largely supportive, focussing on the treat-
ment of signs and symptoms rather than addressing the
underlying lysosomal enzyme deficiency. Disease-specific
therapy for MPS II is now available throughout Europe,
although expertise in diagnosis and managing MPS II
varies widely between countries. Thus, there is a need
for guidance on how to recognise, diagnose and manage
patients with this condition, with particular focus given
to the multidisciplinary approach needed for this multi-
system disease.
This article describes the recommendations developed
by the Hunter Syndrome European Expert Council
(HSEEC) for the diagnosis and management of MPS II.
The HSEEC is a group of European clinicians with sub-
stantial experience of diagnosing and treating patients
with MPS disorders and lysosomal storage diseases
(LSDs). Others with expertise in particular aspects of
the management of MPS II have also contributed to
these recommendations - including specialist clinicians,
a specialist nurse and a representative of a patient
society - with the aim of providing practical guidance
on all aspects of patient care. A full list of contributors
can be found at the front of this article.
Methodology
These recommendations have been developed using an
evidence-based approach. Owing to the rarity of MPS II,
there is a paucity of published data on the management
of this disease, so data from clinical trials, observational
studies, review articles and case studies were all consid-
ered when formulating recommendations. For those
topics for which few or no published data were avail-
able, the information presented is based on the clinical
experience of the authors. Such instances are clearly
indicated in the manuscript as Consensus Opinion (CO).
Search strategy and selection criteria
Literature searches for topics relating to the manage-
ment of patients with MPS II were carried out in
PubMed and EMBASE between 13 July and 16 Septem-
ber 2010, using Medical Subject Heading Terms and
relevant keywords. To ensure relevance to the modern
day clinical setting, literature searches were limited to
articles published since 1 January 1990. Older articles
identified by the authors were also included. Only arti-
cles from the peer-reviewed literature were included in
the literature search. Articles in a non-English language
with an abstract, and articles in the English language
without an abstract were included if they were consid-
ered relevant to the search being carried out. Abstracts
from industry-sponsored meetings were not included.
Diagnosis
MPS II is a progressive disorder that has traditionally
been categorised into a severe form and a mild/attenu-
ated form based on the age at onset of signs and symp-
toms, the presence or absence of neurological
involvement, and length of survival [2]. However, this
classification appears to be a gross oversimplification,
particularly as I2S activity is equally deficient in both
forms of the disease [2]. Rather, the disorder should be
regarded as a continuum of phenotypes between two
extremes [3]. The multisystem nature of MPS II and the
heterogeneity of disease progression mean that patients
may present with many different signs and symptoms to
a wide range of specialists. Characteristic features of
MPS II include coarsened facial features, an enlarged
head, an enlarged tongue, hypertrophic tonsils and ade-
noids, irregularly shaped teeth, recurrent otitis media, a
distended abdomen due to hepatosplenomegaly, abdom-
inal and/or inguinal hernias, and thickened pebbled skin
(Figure 1) [11,14]. Patients with MPS II also exhibit
short stature, although children with severe phenotypes
are often initially taller than their peers, before growth
slows [12]. Other signs and symptoms can result from
changes to the musculoskeletal system, eyes, gastroin-
testinal tract, airways and cardiovascular and nervous
systems. Although the specific combination of signs and
symptoms may vary considerably between individuals,
the presence of any of the features listed may be sugges-
tive of MPS II. The evolution of signs and symptoms is
often a better indicator of a diagnosis of MPS II than a
static snapshot of the presence or absence of certain
manifestations. Therefore, it is important to monitor
changes in signs and symptoms over time (CO).
A suspected diagnosis of MPS II should be confirmed
by biochemical or genetic analysis. An algorithm for
testing for MPS II is shown in Figure 2. Quantitative
and qualitative analysis of urinary GAGs is useful as a
preliminary screening test to help establish that an indi-
vidual has a form of MPS; however, this does not con-
firm a specific diagnosis of MPS II [2]. The ‘gold
standard’ for the diagnosis of MPS II in a male proband
is demonstration of deficiency of I2S enzyme activity in
leukocytes, fibroblasts, or plasma. Measurement of I2S
activity in dry blood spots also represents a valuable
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Page 2 of 18method for screening, as no heparin is needed and very
little blood is required. Dry blood spots are stable for
several days at room temperature so transportation of
samples is easy [15], and this may extend testing to
areas some distance from diagnostic centres, which are
not widely available. Documentation of normal enzyme
activity of at least one other sulfatase is critical, as low
levels of I2S activity are also characteristic of multiple
sulfatase deficiency [11]. Finally, molecular genetic test-
ing of IDS to confirm the diagnosis may be useful in
male patients with an unusual phenotype or in whom
the results of I2S testing are inconclusive [16]. Molecu-
lar genetic testing of IDS is also important for genetic
counselling, especially if there is no known family his-
tory of MPS II. Once the disease-causing mutation has
been identified, a detailed pedigree analysis should be
carried out to identify family members who may be car-
riers of a disease-causing mutation or at risk of the dis-
ease, and genetic counselling should be offered to all
family members.
Prenatal diagnosis and pre-implantation genetic diag-
nosis can be useful for identifying affected embryos in
at-risk pregnancies [17]. Although it is beneficial to have
identified the disease-causing mutation in the family
[18], it is not always necessary for prenatal diagnosis. If
the mother has been diagnosed as an obligate carrier
through her family history, assays for the I2S enzyme
and GAG levels may be conducted on cells from amnio-
tic fluid, in chorionic villus biopsy tissue or cord blood
[19,20], allowing early testing and rapid diagnosis of
affected foetuses.
Females with MPS II are very rare. They are typically
heterozygous for this X-linked disorder and most are
asymptomatic ‘carriers’ with normal or slightly reduced
I2S activity [3]. Some heterozygous females have been
found to develop signs and symptoms because of struc-
tural abnormalities of the × chromosome or skewed
inactivation of the paternal × chromosome [7,8,21-25].
There has also been one report of a female patient who
was homozygous for a disease-causing point mutation
[9]. The most reliable method of diagnosing MPS II in
affected females and carriers is to test for a family-speci-
fic mutation that has been identified in an affected male
relative [3,16]. Sequence analysis of the entire IDS cod-
ing region may be necessary if a family-specific mutation
is not known. An alternative is first to sequence the
exons with the highest prevalence of mutations (e.g.
exon IX) or search for recurrent mutations (e.g. p.
S333L). Complex rearrangements between IDS and its
pseudogene, IDS2, can also be detected by PCR.
Assessing disease severity
The advent of an effective treatment for MPS II has
highlighted the need for a standardised method for
monitoring the progression of patients with this disease
and their response to therapy. There is currently no
standardised severity scoring system for MPS II. Biomar-
kers such as urinary GAGs and heparin cofactor II-
thrombin complex [26] have been proposed, but neither
has been found to be a specific marker of disease sever-
ity in patients with MPS II [2,27]. Standard functional
tests, such as the Pediatric Evaluation of Disability
Inventory (PEDI) and a test developed by the Pediatric
Orthopedic Society of North America (POSNA) [28,29],
may be applicable to patients with MPS II, but this
requires confirmation in a relevant population [30]. The
validation of a scoring system for such a rare disease as
MPS II represents a significant challenge.
In the absence of a suitable severity scoring system for
MPS II, it is recommended that patients are monitored
closely and undergo a comprehensive physical, biochem-
ical, and behavioural evaluation following diagnosis and
at least every 6-12 months thereafter (CO). More fre-
quent assessment may be necessary in patients in whom
signs and symptoms are progressing rapidly. Where pos-
sible, this should take place at a centre with experience
Figure 1 Characteristic features of mucopolysaccharidosis type
II. Fourteen-year-old boy showing (a) coarsened facial features
(including enlarged head, broad nose with flared nostrils, prominent
supraorbital ridges, large jowls, thickened lips, and irregular peg-
shaped teeth), (b) musculoskeletal manifestations (including short
neck, short stature, and joint stiffness [unable to raise arms above
head]) and (c) abdominal distension due to hepatomegaly and
splenomegaly. (d) Tracheomalacia seen at airway endoscopy. (a)-(b)
reproduced with permission from Martin and colleagues [11],
Copyright
© 2008 by the AAP; (a)-(c) courtesy of Professor Joseph
Muenzer; (d) courtesy of Dr Iain Bruce.
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Figure 2 Diagnostic algorithm for mucopolysaccharidosis type II (MPS II). The ‘gold standard’ for the diagnosis of MPS II in a male proband
is demonstration of deficiency of iduronate-2-sulfatase enzyme activity in leukocytes, fibroblasts, or plasma. Measurement of iduronate-2-sulfatase
activity in dry blood spots also represents a valuable method for diagnosis, as no heparin is needed and very little blood is required. GAGs =
glycosaminoglycans. IDS = iduronate-2-sulfatase gene. LSD = lysosomal storage disease. MPS = mucopolysaccharidosis. MSD = multiple sulfatase
deficiency.
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of the musculoskeletal and cardiovascular systems, ears,
airways, eyes, skin, nervous system, abdomen and gas-
trointestinal system, as outlined in Table 1. Many exam-
inations are dependent on patient cooperation, so
proper evaluation may be difficult in very young patients
or individuals with cognitive dysfunction. It is important
to note that the development of many of the individual
signs and symptoms of mucopolysaccharidoses is irre-
versible; therefore, slowing or halting disease progres-
sion should be considered an important outcome in
patients receiving treatment (CO).
Disease-specific approaches to treating MPS II
Once a diagnosis of MPS II has been confirmed, the
available treatment options should be discussed with the
patient and his or her parents. An explanation of poten-
tial treatment outcomes and adverse events should be
given, and realistic treatment goals should be set (CO).
Enzyme replacement therapy (ERT) with recombinant
I2S (idursulfase, Elaprase
®; Shire Human Genetic Thera-
pies, Inc., Cambridge, MA, USA) is commonly used to
treat MPS II [3]. Alternatives such as stem cell trans-
plantation (STC) using umbilical cord blood, peripheral
blood haematopoietic cells or bone marrow have also
been used, but they appear to offer limited clinical bene-
fits in patients with this disease and have been asso-
ciated with a serious risk of morbidity and mortality
[31,32]. In many centres, STC is no longer proposed as
a therapy for MPS II, although it must be stated that
the literature is biased by the reporting of very poor
outcomes in patients treated after the onset of signifi-
cant cognitive decline (CO). Very few boys have
received SCT in the early weeks or months of life (see
below).
Enzyme replacement therapy
Idursulfase is a purified form of I2S, produced by
recombinant DNA technology in a continuous human
cell line. Intravenous ERT with idursulfase provides exo-
genous enzyme for selective uptake into cells via man-
nose-6-phosphate receptors on the cell surface [33].
Upon internalisation, the enzyme is transferred and
localised within lysosomes, where it catabolises accumu-
lated GAGs [3].
Idursulfase is indicated for the long-term treatment of
patients with MPS II. In a randomised, placebo-con-
trolled clinical trial, intravenous administration of idur-
sulfase (0.5 mg/kg body weight weekly for up to 53
weeks) to 32 patients was associated with significant
improvements in a composite endpoint comprising
change in distance walked in 6 minutes and percentage
of predicted forced vital capacity (%FVC) compared with
patients receiving placebo (p = 0.0049) [34]. When
evaluated individually after 53 weeks, the increase from
baseline in mean (± SEM) distance walked in the 6-min-
ute walk test was significantly greater in patients receiv-
ing idursulfase compared with those given placebo (+44.3
±1 2 . 3mv e r s u s+ 7 . 3±9 . 5m ,r e s p e c t i v e l y ;p=0 . 0 1 3 1 ;
Figure 3a). %FVC increased more from baseline in
patients treated with idursulfase than in the placebo
group, although this difference did not reach significance
(p = 0.0650; Figure 3b) [34]. The mean increase in abso-
lute FVC from baseline was significantly greater in
patients treated weekly with idursulfase compared with
placebo (+0.22 ± 0.05 L versus +0.06 ± 0.03 L; p =
0.0011; Figure 3c). The mean decrease in liver volume at
53 weeks was significantly greater in patients treated with
idursulfase compared with placebo (-25.3 ± 1.6% versus
-0.8 ± 1.6%, respectively; p < 0.0001) as was the change in
spleen volume (-25.1 ± 2.4% versus +7.2 ± 4.2%, respec-
tively; p < 0.0001) [34]. Urinary GAG levels were signifi-
cantly reduced from baseline in patients receiving ERT
compared with placebo (mean change, -189.2 ± 25.8 μg/
mg creatinine vs. +18.2 ± 29.9 μg/mg creatinine, respec-
tively; p < 0.0001; Figure 3d) [34]. Aside from an
improvement in elbow mobility between the weekly idur-
sulfase group compared with placebo (p = 0.0476), no
other significant differences between treatment groups
for any joint range of motion were found [34].
Following this trial, a 2-year open-label extension
study of weekly idursulfase was undertaken in a popula-
tion of all 94 patients that completed the Phase II/III
study [35]. Although %FVC did not change significantly
except at a single timepoint, there was a sustained
improvement in mean absolute FVC compared with the
initial study’s baseline (mean change at 3-year timepoint,
+0.31 ± 0.06 L, 25.1%; p < 0.05) [34,35]. Increases in dis-
tance walked in 6 minutes compared with baseline were
maintained, although variable from one assessment to
another. The largest increase was seen at 20 months
after the start of the initial study - a mean increase of
42 ± 10 m from baseline (p < 0.01) [35]. Effects on liver
and spleen volume were also maintained, and a sus-
tained reduction in urinary GAG levels was observed
during 3 years of treatment, with a final mean value of
81.7 μg/mg creatinine (well below the upper limit of
normal) [35]. Joint range of abduction and flexion-
extension improved for the shoulder to a degree felt to
be clinically important (approximately 12° and 15°,
respectively, at 36 months; both p ≤ 0.005) and
remained stable in the elbow, wrist, digits, hip, knee and
ankle [35]. After 24 months, both parent- and child-
assessed measures of quality of life showed significant
improvements from baseline (change in parent-assessed
Disability Index Score, -0.13 ± 0.06, p = 0.047; change
in child-assessed Disability Index Score, -0.15 ± 0.65, p
= 0.031) [35].
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Presenting feature Assessment method
General appearance
Enlarged head Clinical examination (including measurement of head circumference),* family
history*
Coarse facial features (broad nose with flared nostrils,
prominent supraorbital ridges, large jowls, thickened lips)
Clinical examination*
Irregular, peg-shaped teeth Clinical examination*
Hyperplasic and hypertrophic gingival tissue Clinical examination*
Cardiovascular system
Right and left ventricular hypertrophy Echocardiogram,* chest X-ray,* cardiac MRI,† CT scan†
Arrhythmia, irregular heartbeat Clinical examination,* electrocardiogram,* Holter monitoring†
Heart failure Echocardiogram,* electrocardiogram,* CT scan,† metabolic or perfusion imaging
(positron emission tomography and single photo emission computer tomography)†
Changes to mitral, aortic, tricuspid and pulmonary valves Echocardiogram,* cardiac MRI†
Hypertension Clinical examination*
Nervous system
Developmental delay Medical history (achievement of developmental milestones),* neurobehavioral
assessment/cognitive testing,* measurement of intelligence quotient†
Progressive mental impairment (cognitive dysfunction) Neurobehavioral assessment/cognitive testing,* measurement of intelligence
quotient†
Gait disturbance Evaluation of sitting and standing posture and walking ability (6-minute walk test),*
MRI of the brain and cranio-cervical junction†
Seizures MRI of the brain and cranio-cervical junction*, electroencephalography†
Behavioural disturbances (over activity, obstinacy, aggression) Neurobehavioral assessment/cognitive testing,* measurement of intelligence
quotient†
Carpal tunnel syndrome Electrophysiological testing of nerve conduction velocity†
Eye
Loss of vision/visual field Best-corrected visual acuity test,* slit lamp biomicroscopy,* visual field (automated
static or kinetic)*
Elevated intraocular pressure Applanation tonometry*
Retinal pigmentary degeneration Fundoscopy,* retinoscopy/refractometry,* visual field,* optical coherence
tomography,† electroretinography†
Optic nerve involvement (optic disc swelling, papilloedema,
optic atrophy)
Fundoscopy,* visual field,* optical coherence tomography,† visual-evoked potential†
Musculoskeletal system
Short neck and short limbs Clinical examination (including auxological evaluation)*
Short stature Clinical examination (including auxological evaluation)*
Arthropathy, joint stiffness and contractures 6-minute walk test,* joint range of motion (shoulders, elbows, wrists, knees, hips
and ankles)*
Abnormal bone thickness and shape (e.g. malformation of
tarsal bones, pelvis, and vertebral bodies)
X-ray (spine, hips and pelvis)*, radiography†
Claw-like hands Clinical examination*
Spine deformities (kyphosis, scoliosis) Evaluation of standing and sitting posture and walking ability (6-minute walk test),*
cervical spine flexion/extension,* MRI of the cervical spine,† X-ray of the lumbar
spine†
Ear, nose and throat
Enlarged, protruding tongue Clinical examination*
Recurrent ear infections Medical history (frequency of ear infections),* otological and audiological
examinations*
Progressive hearing loss (conductive and sensorineural) Otological and audiological examinations*
Frequent upper respiratory tract infections Medical history (frequency of respiratory infections),* vital signs (pulse, respiratory
rate, blood pressure, and oxygen saturation in air)* spirometry to measure FVC*
Thick nasal and tracheal secretions Examination of upper airway*
Airway
Progressive airway obstruction, tracheobronchomalacia Examination of upper airway for hypertrophy of the tonsils and adenoids, and
tracheal deformities*
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month, open-label, clinical study of 10 adult Japanese
patients with attenuated forms of MPS II [36]. Idursul-
fase has also been found to have a positive influence on
growth in 18 patients with MPS II, especially in children
younger than 10 years of age (Figure 3e) [37]. In this
group a mean height increase of 14.6 cm was seen over
3 years of ERT.
Adverse events associated with ERT
As with any intravenous protein product, anaphylactoid
reactions, which can be life-threatening in extreme
cases, have been observed in some patients treated with
idursulfase [33-35,38]. These hypersensitivity responses
are more commonly known as infusion-related reactions
(IRRs). Late emergent signs and symptoms of IRRs have
been observed as long as 24 hours after an initial reac-
tion [38], although these are often mild and do not
require hospitalisation. Patients who experience moder-
ate-to-severe IRRs should be monitored for at least 24
hours.
In clinical trials, most of the adverse events reported
were related to the underlying disease rather than ERT
[33-36]. The most common treatment-related adverse
events were IRRs (e.g. headache, hypertension, erythema,
pyrexia, flushing, pruritus, urticaria, and/or rash)
[33-36]. In general, rates of IRRs tended to decline over
time (Figure 3f) and no patient discontinued treatment
due to an IRR during clinical studies [34,35]. Immuno-
globulin (Ig) G antibodies occurred in 46.9% of patients
treated with idursulfase, and IgM antibodies, of
unknown importance, were reported in one patient [34].
In approximately half of antibody-positive patients, anti-
body titres fell below the level of detection after contin-
ued treatment [35]. Neutralising antibodies were
detected in 22 out of 94 patients. Changes in distance
walked in 6 minutes, liver and spleen volume and urin-
ary GAG levels did not appear to be affected by neutra-
lising antibody status [35]. However, individuals with
neutralising antibodies showed smaller increases in
absolute FVC compared with patients without neutralis-
ing antibodies [35]. Further studies into the long-term
impact of neutralising antibodies on clinical response
are needed.
Serious adverse events were reported in a minority of
patients in clinical trials [33-35]. In the randomised pla-
cebo-controlled clinical trial, two deaths occurred [34].
Both were associated with pulmonary infections and one
of the patients died following a cardiac arrest. Neither
death was considered to be related to the study medica-
tion. In the subsequent 2-year extension study, one
further death occurred owing to upper airway obstruc-
tion [35]. Again, this was not considered to be related to
the study drug. Hypoxic episodes during enzyme infu-
sion, which necessitate oxygen therapy, have been
reported in patients with severe underlying obstructive
airway disease (sometimes with pre-existing tracheost-
omy). In one patient with a febrile respiratory illness,
idursulfase administration was associated with hypoxia
during the infusion, resulting in a short seizure [33].
These events did not recur with subsequent administra-
tion using a slower infusion rate and premedication
with low-dose corticosteroids, antihistamines and beta-
agonist nebulisation.
Administration of ERT
Idursulfase should be administered weekly at a dose of
0.5 mg/kg body weight by intravenous infusion over 3
hours. Although the drug’s prescribing information
states that the infusion period may be gradually reduced
Table 1 Close monitoring of patients with mucopolysaccharidosis type II is necessary. (Continued)
Sleep apnoea Sleep study (assessment of thoracic and abdominal motion; pulse oximetry to
measure arterial oxygen saturation and pulse rate; electrocardiography)*
Skin
Thickened and inelastic skin Clinical examination*
Pebbly, ivory-coloured skin lesions Clinical examination*
Abdomen/gastrointestinal system
Hepatomegaly Clinical examination,* abdominal ultrasound,* abdominal MRI†
Splenomegaly Clinical examination,* abdominal ultrasound,* abdominal MRI†
Bladder obstruction Abdominal ultrasound*
Chronic diarrhoea Medical history*
Umbilical and/or inguinal hernias Clinical examination*
Psychological wellbeing
Poor quality of life Patient interview,* patient-completed quality of life questionnaires (e.g. Child Health
Assessment Questionnaire Disability Index Score [CHAQ DIS], Short Form 36 Health
Survey [SF-36])†
Characteristic features of mucopolysaccharidosis type II and the methods available to assist diagnosis [2,3,11,12,46,47,57,75,80,81,84,88,89,97,98,108-129].
All assessments are subject to patient cooperation; *Essential assessment. †Optional assessment.
CT = computed tomography. FVC = forced vital capacity. MRI = magnetic resonance imaging.
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Figure 3 Clinical effects of enzyme replacement therapy (ERT) with idursulfase (0.5 mg/kg weekly) or placebo in patients with
mucopolysaccharidosis type II (MPS II).( a) Mean (± SE) change from baseline in distance walked in 6-minute walk test; (b) mean (± SE)
change from baseline in percentage of predicted forced vital capacity; (c) mean (± SE) change from baseline in absolute forced vital capacity; (d)
mean (± SE) change from baseline in concentration of urine glycosaminoglycans; (e) mean (± SD) growth velocity before and during enzyme
replacement therapy; (f) incidence of infusion reactions during treatment with idursulfase. Absolute forced vital capacity is a better measure of
respiratory function than percentage of predicted forced vital capacity, as the latter assumes both normal growth and height, which does not
apply to patients with MPS II. (a-d) adapted from [34] with permission; (e) reproduced from [37] with kind permission from Springer Science &
Business Media; (f) reproduced from [35] with permission. *p = 0.0131; **p = 0.011; ***p < 0.0001, compared with placebo based on analysis of
covariance. SD = standard deviation. SE = standard error. ANCOVA = analysis of covariance. FVC = forced vital capacity. ERT = enzyme
replacement therapy.
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Page 8 of 18to 1 hour if no IRRs are observed, shortening the infu-
sion time substantially is undesirable, as it may increase
the risk of IRRs (CO). Infusion should be supervised by
a physician or other healthcare professional experienced
in the management of patients with MPS II or other
inherited metabolic disorders. Delivery methods include
use of a venous cannula or of a totally implantable
venous access device, which is placed under general
anaesthetic. The patient should be observed closely
throughout the infusion and vital signs should be moni-
tored regularly. Caution is required for patients with a
febrile infection, airway abnormalities, respiratory dis-
tress, or a history of allergies. Reduction in infusion rate
and premedication with antihistamines, antipyretics and/
or low-dose corticosteroids may be used to reduce the
risk of IRRs. Premedication should be given no more
than 30 minutes before starting the infusion (CO).
Following a change to the European product license
for idursulfase in March 2010, infusion of ERT at home
can now be considered for some patients. Although
‘homecare’ i sn o tp r o v i d e di na l lc o u n t r i e si nE u r o p e ,i t
has been associated with increased patient adherence
compared with receiving infusions in hospital, and
patients and families often report improved quality of
life [39-41]. Safety is the primary consideration when
providing ERT in the home setting, and strict protocols
have been developed to manage the transition from hos-
pital to home care (Figure 4) [42]. Prior to initiation of
homecare, the patient’s home must be assessed to
ensure that it is safe for both the child and the nurse
delivering the infusion [43,44]. Patients must have
received ERT in hospital for 3-6 months; if patients
have previously had IRRs, they must be under control
with premedication, and they must not have had an IRR
in the 2-8 weeks before homecare is approved and pre-
medication must be given [44]. If a patient has signifi-
cant respiratory disease (%FVC, 40% or less; or evidence
of serious obstructive airway disease), homecare may
not be suitable [44].
Considerations for initiating and ending treatment
Many patients with MPS II will develop potentially life-
threatening manifestations by the second decade of life,
so timely treatment is important. The relationship
between progressive GAG storage and clinical manifes-
tations in MPS II provides a strong argument for the
initiation of ERT as early as possible following diagnosis
(CO). Clinical trials of idursulfase demonstrated clinical
benefits of treatment in patients older than 5 years
[33,34,36], but experience of ERT in younger children is
growing [45]. Some national guidelines recommend that
ERT should be initiated for all patients with a biochemi-
cally confirmed diagnosis of MPS II, including those
younger than 5 years [46].
Idursulfase does not cross the blood-brain barrier.
Thus, it will not affect the cognitive and behavioural
manifestations of MPS II. Weekly intravenous therapy
can place a significant burden on both the patient and
their family [3,47]; nonetheless, even for patients with
advanced disease, ERT may significantly improve quality
of life through improvements in respiratory function,
organomegaly, and joint mobility [3,47]. In some coun-
tries it is recommended that for patients older than 5
years who already have evidence of considerable cogni-
tive decline, the decision to initiate treatment should be
at the clinician’s discretion, in discussion with the child’s
parents [46]. Owing to the heterogeneous nature of
MPS II and the variable rate of progression, it would
Commence ERT in clinic
Evaluation for home therapy
Continue ERT
in the clinic
Re-evaluation on a
regular basis
12–16 weeks
Yes
Yes
No
No
Patient fulfils criteriaa
Referral to home
healthcare team
Home
environment suitable 
for home therapyb
Agreement for transition
Start of home therapy
Key
= Start/finish
= Next step in transition
= Decision point
Figure 4 Algorithm for the provision of enzyme replacement
therapy (ERT) outside of the hospital setting.
aPatient aged 5
years or older, with no infusion-related reactions, with stable airway
disease and established intravenous access.
bUnder some
circumstances, an environment other than the home, such as
school, may be considered as an alternative to the clinic. Adapted
from [42] with permission from Elsevier.
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Page 9 of 18seem reasonable to offer ERT to all patients for a ‘trial’
period of at least 12-18 months, regardless of phenotype,
after which time a decision should be made, in consulta-
tion with the parents, as to whether to continue (CO).
Short- and long-term effects of treatment continuation
or cessation on the patient’s quality of life should be the
primary concern. Thus, any evidence of central nervous
system (CNS) disease progression should be taken into
consideration when formulating a management strategy
(CO).
ERT is not indicated for patients who are pregnant or
lactating, or in individuals whose disease is so far
advanced that there is little prospect of ERT having any
benefit [46]. There are no published data concerning
any effect of idursulfase on spermatogenesis; therefore,
men with MPS II should continue to receive ERT when
trying to conceive (CO). Treatment is also not recom-
mended if the patient has a comorbid life-threatening
disease for which the prognosis is unlikely to be influ-
enced by ERT [46].
Treatment should be discontinued for patients with
life-threatening IRRs that are not adequately prevented
or controlled by antihistamines and corticosteroids
(CO). In these circumstances, the possibility of poten-
tially fatal sudden respiratory failure is high.
Stem cell transplantation
Transplantation of stem cells using bone marrow, per-
ipheral blood haematopoietic cells or umbilical cord
blood has been shown to be effective in slowing disease
progression in selected lysosomal and peroxisomal
inherited metabolic storage diseases, including MPS IH
(Hurler syndrome), MPS VI (Maroteaux-Lamy syn-
drome), X-linked adrenoleukodystrophy, metachromatic
leukodystrophy and globoid-cell leukodystrophy (Krabbe
disease) [48-54]. SCT relies on the progressive replace-
ment throughout the body of endogenous haematopoie-
tic lineage cells with exogenous cells transplanted from
a healthy donor. Importantly, experiments in mice have
shown that the transplanted cells can migrate across the
blood-brain barrier, differentiate into microglia, and
express lysosomal enzymes that can be taken up by cells
in the CNS and delivered to the lysosome [55]. This,
coupled with the apparent inability of enzymes adminis-
tered intravenously to cross the blood-brain barrier, has
stimulated interest in the therapeutic potential of STC
f o rp r e v e n t i n go rt r e a t i n gt h en e u r o l o g i c a lm a n i f e s t a -
tions of metabolic storage diseases, including MPS II.
At the time of writing, no controlled clinical studies
have been conducted to evaluate the effects of bone
marrow transplantation (BMT), haematopoietic stem
cell transplantation (HSCT) or umbilical cord blood
transplantation (UCBT) in patients with MPS II; with
experience limited to single published case studies or
small case series. This is hardly surprising given the rar-
ity of MPS II, and it is unlikely that formal randomised
controlled trials will ever be conducted.
The use of STC for the treatment of MPS II is contro-
versial because of the profound risk of morbidity and
mortality associated with this treatment approach [31].
Many patients receive immunosuppressant and steroid
medication following transplantation to protect against
or alleviate graft-versus-host disease [56]. However, the
use of immunosuppressants can leave the patient vul-
nerable to infection, and the chronic use of steroids may
lead to orthopaedic complications (e.g. osteonecrosis of
the hip) [47].
Bone marrow transplantation
The majority of clinical experience of BMT in patients
with MPS II comes from observations made in case stu-
dies. At the time of writing, only two studies have exam-
ined the long-term outcomes of BMT in groups of four
or more patients with MPS II [31,32]. In these studies,
BMT was found to increase or normalise I2S activity in
leukocytes, but not serum, and was associated with
decreased or normalised urinary GAG excretion in
patients with MPS II [31,32]. The long-term outcomes
of BMT appear unpredictable in patients with MPS II,
perhaps owing to the heterogeneity of the disease. Reso-
lution of hepatosplenomegaly, improvement of upper
airway obstruction, progressive resolution of coarsened
facial features, reduced joint stiffness, stabilisation of
perceptual hearing defects and improvement in trans-
mission hearing defects were all reported [32]. Cardiac
structure and function were found to stabilise in some
patients [32]; an important finding given that cardiac
failure is a common cause of death in individuals with
MPS II [57]. However, no quantitative data are available
for any of these observations.
BMT does not appear to improve neurological func-
tion in patients with a severe phenotype if they already
have signs of developmental delay or neurological invol-
vement at transplantation [31,32]. By contrast, stabilisa-
tion of neurological function following BMT has been
reported in patients with MPS II with an attenuated
phenotype who were followed for 7-17 years [32].
Whether this observation can be attributed to BMT is
unclear.
Observations from individual case studies include sta-
bilisation of disease, resolution of hepatosplenomegaly
and skin tightness, and improved joint mobility and
growth, each contributing to increased quality of life
[58-61]. Clearance of GAGs from hepatocytes has also
been described [62]. Reports on the effect of BMT on
the progression of neurological manifestations are
inconsistent, with no deterioration in some patients
[59], but clear deterioration in others despite transplan-
tation at a young age [63].
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As with BMT, there are very few data on the effects on
HSCT in patients with MPS II. Notable observations
include a reduction in levels of a urinary marker of
GAG levels (measured as dermatan sulphate to chon-
droitin sulphate ratio) in one patient [64], and complete
resolution of skin papules and a progressive reduction
in skin tightness in five boys (aged 4-11 years) within 35
days of HSCT [65].
Umbilical cord blood transplantation
Improvement or complete resolution of hepatomegaly
has been reported in patients with mild and severe
forms for MPS II following UCBT [56,66]. Urinary GAG
excretion was normalised in a patient with an attenuated
form of MPS II, and growth and development remained
normal up to 2 years after transplantation [56]. No
other physiological changes following UCBT have been
reported. Detection of very low I2S levels in the brain of
ap a t i e n tw i t has e v e r ef o r mo fM P SI Is u g g e s t st h a t
stem cells delivered by UCBT may be able to penetrate
the CNS in individuals with MPS II, although enzyme
levels were insufficient for metabolic improvement [66].
Overall, it appears that SCT can have some beneficial
effects on the peripheral signs and symptoms of MPS II.
However, it is clear that this approach does not preserve
or improve neurological function in patients with severe
forms of MPS II if they already show signs of neurologi-
cal deterioration. The long-term effects of BMT, HSCT
a n dU C B To nn e u r o l o g i c a lf u n c t i o ni np a t i e n t sw i t h
more attenuated forms of MPS II require further study.
In the absence of a clear long-term effect on the neuro-
logical manifestations of MPS II, the potential clinical
benefits of successful engraftment do not appear to out-
weigh the immediate and medium-long-term risks of
the procedure, particularly when other effective and
well-tolerated treatments for peripheral manifestations
are available (CO).
Therapies in development
Owing to the dearth of therapeutic options for alleviat-
ing the neurological manifestations of LSDs, much
research has focused on the development of well-toler-
ated therapies that can cross the blood-brain barrier.
One approach that has been explored is the infusion of
ERT into the cerebrospinal fluid, thereby enabling wide-
spread distribution throughout the CNS. Experiments in
animal models have yielded promising results [67], and
a study into the feasibility and safety of intrathecally
delivered idursulfase in patients with MPS II is
underway.
Other areas of research include the use of pharmaco-
logical chaperones, gene therapy and substrate reduction
therapy. Although a comprehensive overview of these
therapeutic options is beyond the scope of this article,
all have been found to cross the blood-brain barrier and
promising findings have been reported in vitro and in
animal models [68-72]. It is hoped that in the near
future these therapies may help to prevent or reverse
the neurological manifestations observed in patients
with severe forms of MPS II.
Non-disease-specific approaches to managing
MPS II
The wide range of effects of MPS II on the body and the
severity of many of the manifestations mean that most
patients will require substantial medical and surgical
support, even if they are receiving ERT or have received
SCT. A full review of this broad topic is not possible
here, so key aspects of multidisciplinary care are
presented.
Management of cardiovascular manifestations
Cardiovascular manifestations develop at a young age in
patients with MPS II, and most patients exhibit at least
one cardiovascular sign or symptom by the second dec-
ade of life [3]. Typical changes include valve disease (e.g.
changes in morphology and impaired function: affecting
mitral, aortic, tricuspid and pulmonary valves in
decreasing frequency), ventricular hypertrophy, hyper-
tension, and arrhythmia (e.g. tachycardia, bradycardia,
atrioventricular block) [3,14,73]. The progression of car-
diac involvement must be monitored closely, and
patients should undergo regular echocardiography, elec-
trocardiography, and Holter monitoring, if indicated
(Table 1).
Valve disease affects more than half of patients and
can lead to ventricular hypertrophy or heart failure
[3,12]. In some countries, prophylactic antibiotic therapy
may be given before any surgical or major dental proce-
dure as a precaution. However, this practice is no longer
recommended by the National Institute for Health and
Clinical Excellence [74]. Valve replacement has been
reported, but remains uncommon [75,76]. Hypertension
is typically under-diagnosed in patients with MPS II and
should be treated using standard agents, such as angio-
tensin-converting enzyme inhibitors, angiotensin recep-
tor blockers, diuretics and calcium-channel blockers
(CO). Arrhythmias should be treated with ablation, anti-
arrhythmic drugs, anticoagulants and, if necessary, pla-
cement of an implantable cardioverter defibrillator (CO).
Management of neurological involvement
Depending on disease severity, neurological manifesta-
tions of MPS II may include a delay in achieving devel-
opmental milestones, cognitive impairment and seizures
[11,12]. In addition, communicating hydrocephalus,
spinal cord compression, and carpal tunnel syndrome
(CTS) typically require surgical intervention [47].
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school age should provoke further investigation with
cognitive tests, and behavioural therapy and/or the use
of behaviour-modifying medication may be necessary
(CO). Seizures can usually be controlled by anticonvul-
sant therapy [47]. To avoid unwanted adverse events,
low-dose monotherapy is preferred (CO). For patients
with communicating hydrocephalus or evidence of pro-
gressive ventricular enlargement, a ventriculoperitoneal
shunt can be placed to relieve intracranial pressure
[77,78]. Motor function has been reported to improve
after shunt placement [79].
A common feature of MPS II is progressive compres-
sion of the spinal cord with resulting cervical myelopa-
thy [47,80]. This can lead to reduced activity, difficulty
in rising from a sitting position, paresis and spasticity,
pain or loss of sensation in the upper and lower body,
as well as bladder and bowel dysfunction. Irreversible
cord damage can occur if this is left untreated, so surgi-
cal decompression should be considered as soon as
symptoms occur [81-83]. Similarly, decompression of
the median nerve is recommended for patients with
demonstrated loss of hand sensation and/or function or
abnormal nerve conduction studies (CTS). Both decom-
pression procedures have been associated with rapid
and sustained improvement in sensation and function,
as well as providing pain relief [47,84-87].
Management of ocular manifestations
Ocular involvement in MPS II generally consists of loss
of vision, optic disc swelling, papilloedema, optic atro-
phy and retinal pigmentary degeneration [2,88]. Corneal
clouding is almost never encountered [2]. Treatment of
ocular complications in patients with MPS II does not
differ substantially from approaches used for otherwise
healthy individuals (see Table 1). If glaucoma occurs,
most patients respond well to intraocular pressure-low-
ering eye drops (CO). If optic nerve involvement occurs
due to raised intracranial pressure, this should be
addressed using standard methods. Unfortunately, optic
involvement associated with GAG accumulation or ret-
inal degradation cannot be treated, although patients do
benefit from magnifying devices when reading (CO).
Management of musculoskeletal manifestations
Typical musculoskeletal manifestations of MPS II
include short stature, spine deformities, joint stiffness,
contractures, and claw-like hands [89]. Orthopaedic
therapy should be considered for patients with muscu-
loskeletal manifestations, as this can help to address psy-
chosocial aspects of the disease, such as loss of mobility
and independence, as well as relieving the symptoms
themselves. Non-surgical approaches include
physiotherapy and the use of orthopaedic devices, such
as orthotic footwear, braces, corsets and walking aids, to
assist with daily living activities. These approaches can
also help maximise muscle strength and range of move-
ment [89]. Surgical procedures include decompression
of the spinal cord or median nerve, instrumented fusion
(to stabilise and strengthen the spine), arthroscopy, hip
or knee replacement, and correction of the lower limb
axis [89,90].
It has been suggested that recombinant human growth
hormone (GH) may help overcome short stature in
patients with MPS II [91]. GH therapy has been shown
to be well tolerated and effective in improving linear
growth in patients with GH deficiency, Turner syn-
drome and other growth disorders [92-94]; however,
experience in patients with MPS II is very limited. The
only published report of GH therapy in patients with
MPS II is provided by Polgreen & Miller, who observed
transient increases in growth velocity in two patients
treated for up to 1 year [91]. Although GH therapy was
well tolerated in these patients, there are currently insuf-
ficient data on the safety and efficacy of this approach in
children with MPS II to recommend it as a standard of
care (CO). Furthermore, rapid growth carries the theo-
retical risk of worsening of orthopaedic complications
typically observed in patients with MPS II [95]. With
this in mind, patients with MPS II who are prescribed
GH therapy must be followed closely by orthopaedic
physicians who are familiar with MPS diseases [96].
Management of ear, nose and throat manifestations
Ear, nose and throat features of MPS II include hearing
loss, recurrent otitis media, an enlarged tongue, hyper-
trophic adenoids and tonsils and progressive airway
obstruction [97,98]. Chronic and recurrent (more than
six episodes per year) upper-respiratory tract infections
are common, and affected patients may benefit from
analysis of functional antibodies to Streptococcus pneu-
moniae and Haemophilus influenzae, with booster vacci-
nations being provided when appropriate (CO). In the
absence of a correctable immune deficiency, adenoton-
sillectomy or ventilation tube insertion may be appropri-
ate for patients with severe signs and symptoms (CO). If
hearing loss occurs secondary to persistent middle ear
effusion, the possibility of providing hearing aids or
inserting ventilation tubes should be discussed with the
patient and their parents. Both treatments are effective,
but hearing aids are preferred for children with signifi-
cant comorbidity (CO). Macroglossia secondary to GAG
storage is very difficult to manage. Operations on the
tongue are not indicated in patients with MPS II, as the
risk of postoperative respiratory obstructions is high
(CO).
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Upper airway obstruction is a major contributor to the
premature mortality seen in MPS II [13]. It is thought
to result from progressive deposition of GAGs in the
soft tissues of the throat and trachea, and may lead to
obstructive sleep apnoea [98]. Initial treatments for
obstructive sleep apnoea include nocturnal supplemental
oxygen. Tonsillectomy and adenoidectomy may be per-
formed when these are enlarged [90,97], but, because of
the progressive involvement of the throat and trachea,
improvements may only be partial and/or temporary.
Continuous positive airway pressure (CPAP) can be
used to splint the airway open during sleep, and has
been associated with marked improvements in sleep
quality [98,99], leading to reduced fatigue during the fol-
lowing day and fewer complaints of headache [98]. For
patients for whom CPAP is not well tolerated, tracheost-
omy may be used to bypass the upper airway obstruc-
tion or to support the trachea when there is significant
collapse due to tracheobronchomalacia. However, com-
plications following this procedure are common and can
be life-threatening [100], so caution is advised (CO).
Patients with MPS II should undergo regular examina-
tion of the upper airway for signs and symptoms of
developing airway obstruction, and an overnight sleep
study should be conducted in patients with obstructive
sleep apnoea (Table 1) [47,98]. For a more thorough
evaluation of the airway, bronchoscopy may be per-
formed [47]. Routine monitoring of pulmonary function
is challenging, as spirometry requires the full coopera-
tion of the patient and is effort dependent. It cannot be
used reliably for children younger than 6-7 years of age
and may be impossible for patients with significant CNS
involvement [98].
Surgical intervention
Surgical intervention is often required at a young age to
address the clinical manifestations of MPS II [75,76,90].
The most common procedures are insertion of ventila-
tion tubes, hernia repair, adenoidectomy, tonsillectomy,
and median nerve decompression [90]. Surgery may
sometimes precede diagnosis, so it is important to eval-
uate a patient’s surgical history when a diagnosis of
MPS II is suspected [90].
Management of anaesthetic risk
The short neck, immobile jaw, and pathological changes
in the upper airways make general anaesthesia for
patients with MPS II a difficult and high-risk procedure
[98]. For this reason, it is good practice to consider local
or regional anaesthesia where possible. Combining
minor surgical procedures may be appropriate in some
instances; however, extending the operation time
increases the risks of respiratory complications dramati-
cally, so caution is advised (CO).
Before surgery, the patient should be assessed by a
multidisciplinary team that includes a cardiologist, otor-
hinolaryngologist and anaesthetist. A full cardiac assess-
ment is necessary (CO). The severity of obstructive
sleep apnoea can be assessed with a sleep study or more
formal polysomnography. If possible, flexible nasendo-
s c o p ya n dac o m p u t e dt o m o g r a p h ys c a no ft h ea i r w a y
should be carried out preoperatively to evaluate the
anatomy of the airway [101,102]. Tracheomalacia of the
airway makes visualisation and subsequent endotracheal
intubation problematic (Figure 1e) [103,104]. Extubation
presents another major risk, as postobstruction pulmon-
ary oedema may exacerbate upper-airway obstruction
and has been reported to occur as late as 27 hours after
surgery [97,105,106]. Some patients may be unable to
maintain the airway after extubation, resulting in the
need for urgent reintubation or tracheostomy. Early
extubation can reduce this risk substantially [98]. As a
rule, it is recommended that patients with MPS II
should only undergo surgery at centres with experience
of the perioperative management of individuals with this
disease, and on-site intensive care facilities [98,106].
Social aspects of MPS II
Patients with MPS II and their families generally require
considerable psychological and social support following
diagnosis and before and after treatment. Clinicians
should be prepared to provide guidance on treatment-
related issues and to answer questions concerning car-
rier status and prenatal diagnosis. Genetic counselling
should also be offered to family members.
Patient societies provide vital psychosocial support to
parents and siblings through one-to-one counselling, as
well as providing links to other affected individuals
through befriending schemes and regional family days.
They play a key role in helping patients and their
families to understand their disease, and can make par-
ents aware of disability benefits, respite care, and hous-
ing help for which they may be eligible. Both verbal and
written information is provided regarding issues such as
education, grants, equipment, care plans, independent
living, and pre- and post-bereavement support.
In recent years, patient societies have worked closely
with physicians, specialist nurses and homecare compa-
nies to make new treatment options available to
patients. For instance, in the UK, the Society for Muco-
polysaccharide Diseases [107] played an important role
in enrolling patients into idursulfase clinical trials, and
continues to assist patients who want to take part in
ongoing investigations by ensuring that patients and
their families are adequately supported. Importantly,
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tion on how treatment affects quality of life by encoura-
ging their members to participate in surveys.
Summary and conclusions
MPS II is a rare, inherited disease that affects multiple
organs and systems. The development of ERT with idur-
sulfase has provided a means of addressing the underly-
ing lysosomal enzyme deficiency, and improvements in
certain somatic signs and symptoms have been reported
in clinical studies. Unfortunately, options for alleviating
the neurological manifestations of MPS II remain lim-
ited: intravenously administered idursulfase does not
pass through the blood-brain barrier, and experience of
intrathecal administration of ERT is restricted to small
clinical trials. There are few published data on long-
term outcomes from STC in MPS II, especially regard-
ing neurological function. Further work is required to
ascertain whether the potential benefits of successful
engraftment outweigh the risks of the procedures, parti-
cularly as an effective treatment of certain peripheral
manifestations is already available. Given the heteroge-
neous presentation of this disorder, a wide range of spe-
cialties is likely to be involved in its diagnosis and most
patients require substantial medical, surgical, and psy-
chosocial support. Thus, close collaboration between all
involved in dealing with MPS II is essential if patients
are to be diagnosed as early as possible and treated
safely and effectively.
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